The drug " Levelmap ", created for the treatment of complications COVID-19 from the beginning was planned to be used in rheumatoid arthritis, told the General Director of the Russian biotechnology organization Biocad Dmitry Morozov. "because the world is experience of application of this type of drugs for the treatment of patients with COVID-19, we have perepozitsionirovanie back and began clinical tests ", - quotes RT. in the pack are two syringes that doctors have the ability to put either at the same time or with a slight delay. Then the patient is posted for ten days under observation and Then discharged. Morozov drew attention, because this is a fully original Drug molecules which was created by the Firm. He added that from the beginning the medicine was expected to enter after the beginning of the patient's cytokine storm, but the doctors of the Central clinical hospital of the President Administration of the Russian Federation during clinical trials developed their own mode of use. "As soon as they see that a person has mild shortness of breath or other signs of disease COVID-19, which have the ability to develop into aggravating wealth, they did begin to apply in advance ", -said Morozov. before the press service of the Biocad announced that the Drug will go to the Russian hospital presumably after 3 weeks. in Russia the number of infected coronavirus infection exceeded $ 467 thousand people became victims 5689 patients. Current information on the situation of COVID-19 in Russia and the world presented on the portal stopmanager. Of the Russian Federation. <span style="color:darkgray